First Alzheimer’s drug to slow disease progression expected to get full FDA approval

Dr. Lawrence Honig spoke with CNN Health(link is external and opens in a new window) and Gray Television Washington News Bureau(link is external and opens in a new window) following the FDA’s announcement(link is external and opens in a new window) that lecanemab (sold by Eisai as "Leqembi"), the first drug proven to slow the progression of Alzheimer’s disease (AD) in early stage patients, would be shifted to their traditional approval process. According to Dr. Honig, while many patient considerations remain, this “important advance” marks the beginning of a “new treatment era” for patients with AD.